Artelo Biosciences, Inc (ARTLW)

Etorro trading 970x250

About Artelo Biosciences, Inc

Artelo Biosciences, Inc., an ethical biopharmaceutical company, focuses on developing, licensing, and commercializing cannabinoid therapeutic treatments. Its products pipeline includes ART12.11, a cannabidiol composition for the treatment of inflammatory bowel disease, stroke, and rare/orphan diseases; ART26.12, an endocannabinoid transport protein (FABP5) inhibitor for the treatment of breast cancer, prostate cancer, and neuropathic and nociceptive pain; and ART27.13 for the treatment of cancer and cachexia. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was founded in 2011 and is based in La Jolla, California. Address:

Artelo Biosciences, Inc News and around…

Latest news about Artelo Biosciences, Inc (ARTLW) common stock and company :

Artelo Biosciences Reports First Quarter Fiscal Year 2022 Financial Results and Provides Business Update
12 Jan, 2022 Yahoo! Finance

Complete Enrollment of Phase 1 CAReS Trial Anticipated by End of First Quarter of Calendar Year 2022 $26.4 Million in Cash and Marketable Securities as of November 30, 2021 SOLANA BEACH, Calif., Jan. 12, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical stage pharmaceutical company developing therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system, today reported financial and operating results for the first quarter of its fiscal year

Artelo Anticipates Accelerated Clinical Development for ART27.13 Following Its Classification Change in the United Kingdom
11 Jan, 2022 Yahoo! Finance

SOLANA BEACH, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) announced that the United Kingdom’s Home Office has classified the Company’s lead clinical cannabinoid, ART27.13, as “non-controlled” and, therefore, is no longer considered a Schedule 1 controlled substance, which would impose limitations on its production, possession, and supply. The Home Office is the lead government department tasked with major economic, security and safety policies, including dru

Artelo Biosciences Leadership to Participate on Endocannabinoid Panel at the H.C. Wainwright BioConnect 2022 Virtual Conference
10 Jan, 2022 Yahoo! Finance

Artelo CEO also providing corporate outlook for 2022 at the H.C. Wainwright ConferenceSOLANA BEACH, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage pharmaceutical company developing therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today announced that it will be participating at the H.C. Wainwright BioConnect 2022 Conference being held virtually January 10-13, 2022. Key members of Artelo’s leadersh

Lvm Capital Management Ltd Buys Medtronic PLC, Zoetis Inc, Eaton Corp PLC, Sells AT&T Inc, ...
04 Jan, 2022 Yahoo! Finance

Investment company Lvm Capital Management Ltd (Current Portfolio) buys Medtronic PLC, Zoetis Inc, Eaton Corp PLC, Norfolk Southern Corp, Qualcomm Inc, sells AT&T Inc, Activision Blizzard Inc, SPDR Gold Shares ETF, Conagra Brands Inc, Twilio Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Lvm Capital Management Ltd.

Artelo Biosciences Reports Fiscal 2021 Year-End Financial Results and Provides Business Update
29 Nov, 2021 Yahoo! Finance

$26.8 Million in Cash and Marketable Securities as of November 15, 2021, Expected to Support Operations Well Into 2023SOLANA BEACH, Calif., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical stage pharmaceutical company developing therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system, today reported financial and operating results for the fiscal year ended August 31, 2021 and provided a business update. “We achieved significa

Artelo Biosciences to Present at the Q4 Investor Summit on November 17th
11 Nov, 2021 Yahoo! Finance

Solana Beach, California--(Newsfile Corp. - November 11, 2021) - Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage pharmaceutical company developing therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today announced that management will present at the Q4 Investor Summit, hosted by the Investor Summit Group, being held virtually on November 16-17, 2021.Gregory Gorgas, President and Chief Executive Officer of Artelo Biosciences, is scheduled to

We Think Artelo Biosciences (NASDAQ:ARTL) Needs To Drive Business Growth Carefully
02 Nov, 2021 Yahoo! Finance

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Artelo Biosciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
08 Sep, 2021 Yahoo! Finance

SOLANA BEACH, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage pharmaceutical company developing therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today announced that Gregory Gorgas, President and Chief Executive Officer of Artelo Biosciences, will be presenting at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually September 13-15, 2021. Artelo’s presentation will be

Artelo Biosciences to Present at the Q3 Virtual Investor Summit on August 18th
11 Aug, 2021 Yahoo! Finance

Solana Beach, California--(Newsfile Corp. - August 11, 2021) - Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, today announced that management will present at the Q3 Virtual Investor Summit, hosted by the Investor Summit Group, being held virtually on August 17-18, 2021.Andrew Yates, PhD, Senior Vice President and Chief Scientific Officer is s

Artelo Biosciences Announces Publication of Study Results Comparing the Pharmacological Effects of Plant-Derived Versus Synthetic Cannabidiol in Human Cell Lines
04 Aug, 2021 Yahoo! Finance

Study finds no in-vitro pharmacological difference in the antiproliferative, anti-inflammatory, or permeability effects of purified natural versus synthetic CBD Study further validates Artelo’s strategy to develop a synthetic CBD-cocrystal with enhanced pharmaceutical properties as well as synergistic use of the coformer TMP SOLANA BEACH, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of the

Ladenburg Thalmann to Host R&D Showcase Featuring Artelo Biosciences’ CAReS Study on July 28, 2021
21 Jul, 2021 Yahoo! Finance

LA JOLLA, Calif., July 21, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, today announced that Ladenburg Thalmann & Co. Inc. will host an R&D showcase focused on the Phase 1b/2a Cancer Appetite Recovery Study (“CAReS”), evaluating the Company’s lead drug candidate, ART27.13. The webinar will be hosted by Michael Higgi

Artelo Biosciences Reports Third Quarter Fiscal 2021 Financial Results and Provides Business Update
12 Jul, 2021 Yahoo! Finance

Enrollment in CAReS Study in patients with cancer anorexia on track to deliver first data readout by calendar year-end $10.0 Million of Cash and Cash Equivalents as of May 31, 2021 SOLANA BEACH, Calif., July 12, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system, today reported financial and operating results for the third

Artelo Biosciences to Present at the 2021 Ladenburg Thalmann Healthcare Conference on July 14th
07 Jul, 2021 Yahoo! Finance

LA JOLLA, Calif., July 07, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, today announced that management will be presenting and hosting 1x1 meetings during the Ladenburg Thalmann Healthcare Conference taking place virtually July 13-14, 2021. Gregory D. Gorgas, Artelo’s President and Chief Executive Officer, is schedu

Artelo Biosciences, Inc (ARTLW) is a NASDAQ Common Stock listed in ,

970x250